Knowledge Tree

Relations (1)

related 4.46 — strongly supporting 21 facts

Psilocybin is related to depression as a therapeutic intervention, with clinical studies demonstrating its efficacy in reducing symptoms of depression in patients with life-threatening conditions [1], [2], [3], and [4].

Facts (21)

Sources

Published Studies — Johns Hopkins Center for Psychedelic and ... hopkinspsychedelic.org Johns Hopkins Center for Psychedelic and Consciousness Research 4 facts

referenceA 2024 study published in Psychological Medicine assessed the role of expectancy and suggestibility in a clinical trial comparing escitalopram and psilocybin for the treatment of depression.

claimPsilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer, as demonstrated in a randomized double-blind trial.

referenceThe study 'A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression' by Nayak et al. was published in Psychedelic Medicine in 2023.

referenceDoss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., & Barrett, F. S. published 'Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach' in 'Current Topics in Behavioral Neurosciences' in 2021.

The Montreal model: an integrative biomedical-psychedelic ... frontiersin.org Frontiers in Psychiatry 3 facts

claimPsilocybin currently has stronger evidence than ketamine supporting the therapeutic potential of 'emotional breakthroughs' and mystical experiences in the treatment of depression.

claimKetamine and psilocybin can both produce rapid improvements in psychiatric conditions like depression that persist for days or weeks beyond the excretion of the drugs and their metabolites.

referenceRoss, Bossis, Guss, Agin-Liebes, Malone, Cohen, et al. published 'Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial' in the Journal of Psychopharmacology in 2016 (doi: 10.1177/0269881116675512).

Ancient Roots of Today's Emerging Renaissance in ... link.springer.com Springer 3 facts

referenceSchmidt (2016) conducted a randomized controlled trial demonstrating that psilocybin treatment leads to rapid and sustained symptom reduction in patients with life-threatening cancer suffering from anxiety and depression.

referenceRoland R. Griffiths, Matthew W. Johnson, Michael A. Carducci, Annie Umbricht, William A. Richards, Brian D. Richards, Mary P. Cosimano, and Margaret A. Klinedinst published the study 'Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial' in the Journal of Psychopharmacology in 2016.

claimThere is a robust literature of studies establishing the safety and efficacy of ketamine-assisted treatment for depression (Salahudeen et al. 2020) and increasingly high-quality studies on psilocybin-based therapies for depression (Carhart-Harris et al. 2021; Davis et al. 2020), though larger and more robust clinical trials are still needed.

Medicinal plants and human health: a comprehensive review of ... link.springer.com Springer 2 facts

claimPsilocybin, the active compound in magic mushrooms, is showing promise in phase 2 clinical trials for the treatment of treatment-resistant depression and PTSD.

claimThe FDA has granted breakthrough therapy designation to psilocybin for the treatment of depression.

Neuroimaging in psychedelic drug development: past, present, and ... nature.com Nature 2 facts

perspectiveResearchers have expressed skepticism regarding recent evidence suggesting that psilocybin 'liberates' depressed minds.

referenceCarhart-Harris et al. (2021) conducted a trial comparing the efficacy of psilocybin versus escitalopram for the treatment of depression.

Psychedelics, Sociality, and Human Evolution frontiersin.org Frontiers 2 facts

referenceGoldberg et al. (2020a) conducted a meta-analysis finding that psilocybin has experimental effects on symptoms of anxiety and depression.

measurementPatients with depression, anxiety, or post-traumatic stress disorder (n=24) showed decreased neuroticism and increased extraversion sustained at a 3-month follow-up after psilocybin administration, according to Erritzoe et al. (2018).

Effects of psychedelics on neurogenesis and broader neuroplasticity link.springer.com Springer 1 fact

claimA systematic review and meta-analysis published in the Journal of Affective Disorders in 2022 examined the dose effect of psilocybin on primary and secondary depression.

Altered States of Consciousness, Psychedelics - Academia.edu academia.edu Academia.edu 1 fact

claimResearch into the therapeutic applications of psilocybin has been ongoing for decades, with recent studies indicating positive results for treating depression, anxiety, and addiction.

Psychedelic Drugs News - ScienceDaily sciencedaily.com ScienceDaily 1 fact

claimPsilocybin, the active ingredient in magic mushrooms, is being investigated for its potential to treat depression and anxiety in cancer patients.

Psychedelics and Consciousness: Distinctions, Demarcations, and ... ouci.dntb.gov.ua David B Yaden, Matthew W Johnson, Roland R Griffiths, Manoj K Doss, Albert Garcia-Romeu, Sandeep Nayak, Natalie Gukasyan, Brian N Mathur, Frederick S Barrett · Oxford University Press 1 fact

claimStephen Ross et al. conducted a randomized controlled trial showing rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer, published in the Journal of Psychopharmacology, volume 30, page 1165.

Classification Schemes of Altered States of Consciousness - ORBi orbi.uliege.be ORBi 1 fact

claimRoss et al. (2016) conducted a randomized controlled trial demonstrating that psilocybin treatment leads to rapid and sustained symptom reduction for anxiety and depression in patients with life-threatening cancer.